Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ferozsons LaboratoriesKAR:FEROZ -2.38%70 Interest Coverage is 5.06 as of Mar. 2026, which is 69% below its 10-year median of 16.36. GuruFocus rates KAR:FEROZ with a GF Score™ of 70/100 and a GF Value™ of ₨419.78 (Fairly Valued). The stock has 4 warning signs investors should review. Among 687 Drug Manufacturers companies, Ferozsons Laboratories ranks worse than 65.79% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Ferozsons Laboratories's
Operating Income
for the
three
months ended in Mar. 2026 was ₨472 Mil. Ferozsons Laboratories's Interest Expense for the
three
months ended in Mar. 2026 was ₨-93 Mil.
Ferozsons Laboratories's interest coverage for the quarter that ended in Mar. 2026 was 5.06.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Ferozsons Laboratories's Interest Coverage or its related term are showing as below:
KAR:FEROZ'
s Interest Coverage Range Over the Past 10 Years
Min: 2.45 Med: 16.36 Max: 4518.32
Current: 6.16
KAR:FEROZ's Interest Coverage is ranked worse than 65.79% of 687
companies
in the Drug Manufacturers industry
Industry Median: 12.75
vs KAR:FEROZ: 6.16
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Ferozsons Laboratories Interest Coverage Related Terms
Ferozsons Laboratories Interest Coverage Historical Data
* Premium members only.
The historical data trend for Ferozsons Laboratories's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
KAR:FEROZ vs ZTS, UTHR, VTRS: Interest Coverage Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Ferozsons Laboratories's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ferozsons Laboratories Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ferozsons Laboratories's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Ferozsons Laboratories's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ferozsons Laboratories (KAR:FEROZ) has a Interest Coverage of 5.06 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Ferozsons Laboratories and its competitors. This is 69% below median its historical median of 16.36. Over the past decade, Ferozsons Laboratories' Interest Coverage has ranged from 2.45 to 4,518.32. According to the industry distribution chart, Ferozsons Laboratories ranks #452 out of 687 companies in the Drug Manufacturers industry, placing it in the top 65.8%.
Is Ferozsons Laboratories' Interest Coverage too high?
Ferozsons Laboratories' current Interest Coverage of 5.06 is 69% below median its 10-year median of 16.36. Over the past 10 years, this metric has ranged from a low of 2.45 to a high of 4,518.32. The Drug Manufacturers industry median Interest Coverage is 12.75. Ferozsons Laboratories' value of 5.06 is 60.3% below this industry median. Based on the distribution chart, Ferozsons Laboratories ranks #452 out of 687 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Ferozsons Laboratories has a GF Score™ of 70/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ferozsons Laboratories' Interest Coverage compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Ferozsons Laboratories ranks #452 out of 687 companies for Interest Coverage. This places Ferozsons Laboratories in the lower half of its industry. The industry median Interest Coverage is 12.75. Ferozsons Laboratories' value of 5.06 is 60.3% below this benchmark. Historically, Ferozsons Laboratories' own Interest Coverage has ranged from 2.45 to 4,518.32 over the past decade. While the company's 10-year median is 16.36 vs. the industry median of 12.75, Ferozsons Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.75, based on 687 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ferozsons Laboratories's current Interest Coverage of 5.06 is 60.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Ferozsons Laboratories and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ferozsons Laboratories's current Interest Coverage is 5.06, which is 69% below median its own 10-year median of 16.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ferozsons Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Ferozsons Laboratories (KAR:FEROZ) is currently considered Fairly Valued. The stock's GF Value™ is ₨419.78, compared to a current price of ₨391.89 — trading 6.6% below its estimated fair value. The current Interest Coverage is 5.06, which is 69% below median its 10-year median of 16.36 and 60.3% below the Drug Manufacturers industry median of 12.75. Ferozsons Laboratories' overall GF Score™ is 70/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Ferozsons Laboratories (KAR:FEROZ), the current Interest Coverage is 5.06 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ferozsons Laboratories (KAR:FEROZ) Overvalued in 2026?
Based on GuruFocus' analysis, Ferozsons Laboratories stock appears to be undervalued.
The current stock price of ₨391.89 is trading 6.6% below its estimated GF Value™ of ₨419.78.
GuruFocus considers Ferozsons Laboratories to be Fairly Valued.
Key valuation signals for KAR:FEROZ:
Interest Coverage: 5.06 (69% below median its 10-year median of 16.36)
GF Value™: ₨419.78 vs. price of ₨391.89 (6.6% below fair value)
Industry Position: 60.3% below the Drug Manufacturers median (#452 of 687)
No single metric tells the full story. See the KAR:FEROZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ferozsons Laboratories Ltd is a pharmaceutical company. It is engaged in the import, manufacture, and sale of pharmaceuticals products and medical devices. The company operates in the therapeutic areas of dermatology, anti-infective treatments, gastroenterology, hepatology, cardiology, and diabetes. It manufactures tablets, capsules, syrups, suspensions, creams, and ointments. The company operates in three segments namely Ferozsons, BF Biosciences, and Others. The group sells its products in Pakistan and internationally, of which the majority of the revenue is generated from the sales made in Pakistan.
70GF Score
Get the complete analysis for KAR:FEROZ
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KAR:FEROZ has been successfully added to your 
